Therapixel

Company profile

About Therapixel

Therapixel is one of the leading French software companies specializing in artificial intelligence applied to medical imaging, founded in 2013 by Olivier Clatz (INRIA Sophia Antipolis – Méditerranée) and Pierre Fillard (INRIA Saclay Ile-de-France). The company's mission is to make innovative medical imaging technology accessible to all healthcare professionals by delivering pertinent information at the right time. Therapixel gained international recognition in 2017 by winning the DREAM Digital Mammography Challenge, a global competition involving nearly 1,200 research teams focused on developing algorithms for mammogram diagnostic assistance. The company processed 640,000 anonymous digital mammogram images from over 86,000 patients to develop its breakthrough technology. The company's flagship product, MammoScreen®, is an AI-powered software that assists radiologists in reading digital mammograms to detect and qualify suspicious tissue that may be cancerous. Using deep learning technologies trained on hundreds of thousands of cases annotated by breast radiologist experts and confirmed by biopsy, MammoScreen has demonstrated the ability to detect 42% of cancers one year prior to diagnosis and 38.5% two years prior. The technology reduces reader fatigue, improves consistency, and lowers unnecessary recalls, minimizing patient anxiety. Therapixel initially developed Fluid, a touchless medical imaging navigation system for operating rooms, which was sold to Videomed in June 2020 to allow the company to focus entirely on radiology. The company operates research teams in Paris and software development teams in Nice, France. MammoScreen is both FDA-cleared and CE-marked, and Therapixel complies with ISO 13485 standards. Recent partnerships include Mayo Clinic and Onsite Women's Health, expanding MammoScreen's deployment across major healthcare networks in the United States.

Company description · Therapixel official website